Target intelligence / Profile preview

Histone demethylase (null)

Target
null
Molecular classification
Enzyme, Histone modification, Epigenetic regulator, Oxygenase
01

Overview

Histone demethylases are enzymes responsible for removing methyl groups from lysine or arginine residues on histone proteins, which directly alter chromatin structure and regulate gene expression. They play crucial roles in epigenetic modification, orchestrating transcriptional activation or repression, cell fate, differentiation, and development. Two main classes exist: FAD-dependent amine oxidases (e.g., KDM1A/LSD1) and 2-oxoglutarate/Fe(II)-dependent Jumonji C domain (JmjC) oxygenases (e.g., KDM2A, KDM6A). Dysregulation or mutation of histone demethylases is implicated in cancer, neurodevelopmental syndromes, and other diseases, making them significant therapeutic targets for epigenetic drugs. Note: "Histone demethylase" is not a specific single molecular target but a family name covering many enzymes (e.g., LSD1/KDM1A, KDM6A/UTX, etc.). For drug discovery or structured data, mapping to a specific demethylase gene/protein is critical.

Other names
histone lysine demethylaseKDMJMJDlysine-specific demethylasedemethylase
02

Mechanism of action

Inhibition of demethylase activity—prevents demethylation of histone lysine residues, alters gene expression. Some covalently modify cofactor (e.g., FAD-binding inhibition for KDM1A). Dimethylation state–specific inhibition for some drugs.

03

Biological functions

Regulation of transcription/gene expressionChromatin remodelingCell cycle regulationEpigenetic regulationCellular differentiationCell proliferation and development
04

Disease associations

Cancer (many family members are oncogenes or tumor suppressors)Neurodevelopmental/psychiatric disordersDevelopmental syndromesOther (implicated in inflammation, cardiovascular, and metabolic diseases)
05

Safety considerations

Potential on-target toxicity due to roles in normal development and cell differentiationOff-target epigenetic effectsHematological toxicities reported for LSD1 inhibitors (differentiation syndrome, cytopenias)Concerns of long-term effects on memory and neurodevelopment with systemic inhibition
06

Interacting drugs

Tranylcypromine (inhibits LSD1/KDM1A)

4 more in the full profile.

07

Biomarkers

Overexpression or mutation of specific demethylases (e.g., KDM1A, KDM6A) may be used in cancer subtypingHistone methylation patterns (e.g., H3K4me2, H3K9me2) as potential pharmacodynamic biomarkers

Beyond the preview

Go deeper on Histone demethylase (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone demethylase (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call